The World Health Institution on Monday issued guidance on the use of weight-loss injections amid growing demand and discussion surrounding the medications. While approving drugs like Wegovy and Mounjaro for obesity treatment in adults, the WHO cautioned against viewing them as a singular answer to a complex and escalating global health crisis – obesity currently contributes to at least 2.8 million deaths annually [[3]]. The organization emphasized that pharmaceutical interventions must be paired with comprehensive lifestyle changes to effectively address the root causes of weight gain and related health risks.
Geneva, Switzerland – The World Health Organization (WHO) cautioned Monday that weight-loss injections, while potentially beneficial, are not a standalone solution to the global obesity crisis.
“Let me be clear: treatment alone will not solve the obesity crisis,” said WHO Director-General Tedros Adhanom Ghebreyesus during a press briefing in Geneva. The statement comes as the WHO has approved the use of medications known as GLP-1 receptor agonists, but stresses the importance of a holistic approach to weight management.
The WHO guidelines cover active ingredients including liraglutide, semaglutide, and tirzepatide, which are found in drugs such as Saxenda, Wegovy, and Mounjaro, all used in the treatment of obesity. These medications can be used to treat obesity in adults, the organization stated, but are not recommended for pregnant women.
The WHO emphasized that a healthy lifestyle must be a core component of any treatment plan. Obesity is a major public health concern worldwide, contributing to a range of chronic diseases and reduced quality of life.
“It is extremely important that the use of (GLP-1) does not replace the need for a healthy diet or physical activity,” Tedros added. The organization’s guidance underscores the need for comprehensive strategies to address obesity, rather than relying solely on pharmaceutical interventions.
